2. Search Result
Search Result
Results for "

β-catenin/TCF

" in MedChemExpress (MCE) Product Catalog:

36

Inhibitors & Agonists

1

Fluorescent Dyes

1

Biochemical Assay Reagents

6

Peptides

1

Natural
Products

2

Isotope-Labeled Compounds

1

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12238
    IWR-1
    60+ Cited Publications

    endo-IWR 1; IWR-1-endo

    		 Organoid Wnt Inflammation/Immunology Cancer
    IWR-1 (IWR-1-endo) is a tankyrase inhibitor targeting Wnt/β-catenin (IC50 = 180 nM). IWR-1 compromises critical steps of the canonical Wnt signaling, namely translocation of β-catenin to the nucleus and subsequent TCF/LEF activation and expression of Wnt/β-catenin downstream targets. IWR-1 promotes β-catenin phosphorylation by promoting stability of Axin-scaffolded destruction complexes. IWR-1 can be studied in research for anti-tumor purposes, and diseases such as osteosarcoma, colorectal cancer and psoriasis .
    IWR-1
  • HY-14428
    ICG-001
    Maximum Cited Publications
    64 Publications Verification

    		 β-catenin Apoptosis Cancer
    ICG-001 is an inhibitor of β-catenin/TCF mediated transcription. ICG-001 works by specifically binding to cyclic AMP response element-binding protein with an IC50 of 3 μM. ICG-001 selectively blocks the β-catenin/CBP interaction without interfering with the β-catenin/p300 interaction.
    ICG-001
  • HY-P10925
    Zolucatetide

    FOG-001; I-66

    		 β-catenin Cancer
    Zolucatetide (FOG-001;I-66) is a potent β-catenin inhibitor with an IC50 of <50 nM. Zolucatetide can inhibits β-catenin and T-cell factor (TCF) transcription factor interaction. Zolucatetide inhibits cell proliferation and induces cell cycle arrest in target cells. Zolucatetide exhibits anti-tumor efficacy in mice bearing COLO320DM colon cancer cell (with APC, TP53 mutations) xenografts. Zolucatetide can be used for the study of colon cancer .
    Zolucatetide
  • HY-11035
    WAY-262611
    10+ Cited Publications

    		 β-catenin Wnt Cancer
    WAY-262611 is a Wnt/β-Catenin agonist that increases bone formation rate with an EC50 of 0.63 μM in TCF-Luciferase assay. WAY-262611 is also a Dkk1 inhibitor .
    WAY-262611
  • HY-100760
    Toxoflavin
    5+ Cited Publications

    Xanthothricin; Toxoflavine; PKF-118-310

    		 β-catenin Bacterial Antibiotic Histone Demethylase Infection Cancer
    Toxoflavin (Xanthothricin) is an antagonist of transcription factor 4 (TCF4)/β-catenin complex, also acts as an inhibitor of KDM4A, with antitumor and antibiotic activity .
    Toxoflavin
  • HY-101486
    LF3
    10+ Cited Publications

    		 β-catenin Cancer
    LF3 is an antagonist of the β-Catenin/TCF4 interaction with antitumor activity; has an IC50 of 1.65 μM .
    LF3
  • HY-B1360
    Chlorquinaldol
    5+ Cited Publications

    Chloquinan

    		 Antibiotic Bacterial Fungal β-catenin Apoptosis Infection Cancer
    Chlorquinaldol (Chloquinan) is an antibacterial agent with the potential use in topical skin conditions and vaginal infections. Chlorquinaldol is a β-catenin/TCF4 inhibitor, showing anti-proliferation, anti-migration, and apoptosis-inducing activity in cancer cells .
    Chlorquinaldol
  • HY-122649
    UU-T01

    		β-catenin Cancer
    UU-T01 is a β-catenin inhibitor with a KD of 0.531 μM. UU-T01 binds to the K435, R469 and K508 residues of β-catenin, disrupting the β-catenin/TCF4 protein-protein interaction .
    UU-T01
  • HY-18959
    CWP232228
    5+ Cited Publications

    		 β-catenin Wnt Cancer
    CWP232228, a highly potent selective Wnt/β-catenin signaling inhibitor, antagonizes binding of β-catenin to T-cell factor (TCF) in the nucleus. CWP232228 suppresses tumor formation and metastasis without toxicity through the inhibition of the growth of breast and liver cancer stem cells (CSCs) .
    CWP232228
  • HY-P10392AF
    fStAx-35R TFA

    		Wnt β-catenin Cancer
    fStAx-35R TFA is the hydrocarbon-stapled peptide. fStAx-35R TFA inhibits Wnt/β-catenin signaling pathway by disrupting the β-catenin-TCF interaction. fStAx-35R TFA can be used in cancer research .
    fStAx-35R TFA
  • HY-117163
    FzM1.8
    1 Publications Verification

    		 Wnt β-catenin Cancer
    FzM1.8, derives from FzM1, is an allosteric agonist of FZD4 with pEC50 of 6.4. FzM1.8 binds to FZD4 and activates the WNT/β-catenin pathway, by promoting TCF/LEF transcriptional activity in the absence of any WNT ligand. FzM1.8 stabilizes FZD4 with an increased affinity for heterotrimeric G protein and stimulates the release of the Gβγ subunit that in turn activates PI3K .
    FzM1.8
  • HY-117233
    UU-T02
    1 Publications Verification

    		 β-catenin Wnt Metabolic Disease Cancer
    UU-T02 is a novel potent, selective small-molecule inhibitor of β-Catenin/T-cell factor protein-protein interaction (β-catenin/Tcf PPI) with a Ki of 1.36 μM . UU-T02 inhibits canonical Wnt signaling and the growth of colorectal cancer cells .
    UU-T02
  • HY-Y0315
    Hexane-2,5-dione

    2,5-HD

    		 Drug Metabolite Apoptosis Bcl-2 Family β-catenin Caspase Microtubule/Tubulin Wnt Neurological Disease
    Hexane-2,5-dione (2,5-HD) is an orally active, CNS-penetrant cytotoxic agent . Hexane-2,5-dione reduces BCL-2 and β-catenin/TCF transcriptional activity, increases BAX and active caspase-3 expression, and promotes apoptosis. Hexane-2,5-dione causes an accumulation of neurofilaments within axons in rats. Hexane-2,5-dione can be used for the research of neurodegenerative diseases .
    Hexane-2,5-dione
  • HY-P10392B
    aStAx-35R TFA

    		β-catenin Wnt Cancer
    aStAx-35R TFA, a stapled peptide, antagonizes nuclear form of β-catenin and inhibits Wnt signaling. aStAx-35R TFA inhibits competitively the binding of β-catenin to TCF4. aStAx-35R TFA selectively induces growth inhibition of Wnt-dependent cancer cells .
    aStAx-35R TFA
  • HY-N3393
    Lethedioside A

    		β-catenin Inflammation/Immunology
    Lethedioside A is a Enhancer of split 1 (Hes1) inhibitor with an IC50 of 9.5 μM. Lethedioside A inhibits Hes1 dimer formation. Lethedioside A exhibits weak inhibition of TCF4/β-catenin complex formation. Lethedioside A inhibits nitric oxide production by activated immune cells .
    Lethedioside A
  • HY-119966
    CCT036477

    		Wnt β-catenin PPAR CDK Cancer
    CCT036477 is a Wnt/β-catenin pathway inhibitor. CCT036477 blocks transcription at β-catenin without altering its levels. CCT036477 inhibits proliferation of various cancer cells, development of embryos, and expression of Wnt target genes (PPARδ, Cyclin D1, TCF4, and ID2) .
    CCT036477
  • HY-115543
    β-catenin-IN-37

    		Wnt β-catenin Cancer
    β-catenin-IN-37 is a selective β-Catenin/T-cell factor protein-protein interaction (β-catenin/Tcf PPI) inhibitor. β-catenin-IN-37 inhibits canonical Wnt signaling and the growth of colorectal cancer cells SW480 and HCT116 with the IC50 values of 20 μM and 31 μM, respectively .
    β-catenin-IN-37
  • HY-172393
    TCF4/β-catenin-IN-1

    		β-catenin Apoptosis Caspase MDM-2/p53 Bcl-2 Family Cytochrome P450 Cancer
    TCF4/β-catenin-IN-1 (Compound 8b) is an inhibitor of TCF4/β-catenin, and induces apoptosis. TCF4/β-catenin-IN-1 up-regulates p53, caspase-3, caspase-8, caspase-9 levels and Bax protein expression as well as down-regulates Bcl-2 protein expression. TCF4/β-catenin-IN-1 can inhibit CYP3A4, CYP1A2, CYP2C19, and shows promising cytotoxic activity in cancer cells .
    TCF4/β-catenin-IN-1
  • HY-124826
    BC21

    NSC 109268

    		 β-catenin Cancer
    BC21 (NSC 109268) is a β-catenin/Tcf4 inhibitor with an IC50 of 5 μM. BC21 effectively inhibits the binding of β-catenin to Tcf4-derived peptides and suppresses β-catenin/Tcf4-driven reporter gene activity. BC21 can be utilized in cancer research .
    BC21
  • HY-P11007
    β-catenin inhibitory peptoid

    		β-catenin Wnt Androgen Receptor Cancer
    β-catenin inhibitory peptoid (compound 13) inhibits the β-catenin:TCF interaction with an IC50 of 5.44 µM. β-catenin inhibitory peptoid inhibits both Wnt (IC50 of 0.105 µM) and androgen receptor (AR)-signaling (IC50 of 1.02 µM) in prostate cancer cell lines. β-catenin inhibitory peptoid markedly diminishes cell proliferation of prostate cancer cell lines .
    β-catenin inhibitory peptoid
  • HY-P10392
    aStAx-35R

    		β-catenin Wnt Cancer
    aStAx-35R, a stapled peptide, antagonizes nuclear form of β-catenin and inhibits Wnt signaling. aStAx-35R inhibits competitively the binding of β-catenin to TCF4. aStAx-35R selectively induces growth inhibition of Wnt-dependent cancer cells .
    aStAx-35R
  • HY-12238G
    IWR-1

    endo-IWR 1; IWR-1-endo

    		 Organoid Wnt Inflammation/Immunology Cancer
    IWR-1 (IWR-1-endo) (GMP) is the IWR-1 (HY-12238) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. IWR-1 (IWR-1-endo) is a tankyrase inhibitor targeting Wnt/β-catenin (IC50 = 180 nM). IWR-1 compromises critical steps of the canonical Wnt signaling, namely translocation of β-catenin to the nucleus and subsequent TCF/LEF activation and expression of Wnt/β-catenin downstream targets. IWR-1 promotes β-catenin phosphorylation by promoting stability of Axin-scaffolded destruction complexes. IWR-1 can be studied in research for anti-tumor purposes, and diseases such as osteosarcoma, colorectal cancer and psoriasis .
    IWR-1
  • HY-120917
    BRD1172

    ML320

    		 GSK-3 β-catenin Cardiovascular Disease Neurological Disease Cancer
    BRD1172 (ML320) is a selectivity GSK3β inhibitor with an IC50 of 24 nM for GSK3β over CDK5. BRD1172 significantly inhibits GSK3β-mediated Tau phosphorylation in SH-SY5Y cells, and relieves negative regulation by GSK3β on β-catenin degradation and TCF/LEF promoter activities. BRD1172 can be used for Alzheimer’s disease, cardiac hypertrophy and cancers research .
    BRD1172
  • HY-149858
    β-catenin-IN-7

    		Wnt Cancer
    β-catenin-IN-7 (Compound 9) is a β-catenin inhibitor. β-catenin-IN-7 inhibits the interaction between β-catenin and Tcf-4, and inhibits Wnt-dependent target gene expression. β-catenin-IN-7 has anti-cancer activity .
    β-catenin-IN-7
  • HY-Y0315S
    2,5-Hexanedione-d10

    2,5-HD-d10

    		 Isotope-Labeled Compounds Apoptosis Bcl-2 Family β-catenin Caspase Microtubule/Tubulin Wnt Others
    2,5-Hexanedione-d10 (2,5-HD-d10) is the deuterium labeled 2,5-Hexanedione. Hexane-2,5-dione (2,5-HD) is an orally active, CNS-penetrant cytotoxic agent . Hexane-2,5-dione reduces BCL-2 and β-catenin/TCF transcriptional activity, increases BAX and active caspase-3 expression, and promotes apoptosis. Hexane-2,5-dione causes an accumulation of neurofilaments within axons in rats. Hexane-2,5-dione can be used for the research of neurodegenerative diseases .
    2,5-Hexanedione-d10
  • HY-100760S
    Toxoflavin-13C4

    Xanthothricin-13C4; Toxoflavine-13C4; PKF-118-310-13C4

    		 Isotope-Labeled Compounds β-catenin Bacterial Antibiotic Infection Cancer
    Toxoflavin- 13C4 is the 13C-labeled Toxoflavin. Toxoflavin (Xanthothricin) is an antagonist of transcription factor 4 (TCF4)/β-catenin complex, also acts as an inhibitor of KDM4A, with antitumor activity . Antibiotic properties.
    Toxoflavin-13C4
  • HY-100760R
    Toxoflavin (Standard)

    Xanthothricin (Standard); Toxoflavine (Standard); PKF-118-310 (Standard)

    		 Reference Standards β-catenin Bacterial Antibiotic Histone Demethylase Infection Cancer
    Toxoflavin (Standard) is the analytical standard of Toxoflavin. This product is intended for research and analytical applications. Toxoflavin (Xanthothricin) is an antagonist of transcription factor 4 (TCF4)/β-catenin complex, also acts as an inhibitor of KDM4A, with antitumor and antibiotic activity[1][2].
    Toxoflavin (Standard)
  • HY-164467
    CCT070535

    		Wnt Cancer
    CCT070535 blocks TCF-dependent transcription at the TCF level, with GI50 values of 17.6 μM, 11.1 μM, 11.8 μM and 13.4 μM in HT29 (APC mutant), HCT116 (oncogenic β-catenin), SW480 (APC mutant) and SNU475 (Axin mutant) cells, respectively .
    CCT070535
  • HY-108441
    CCT031374 hydrobromide

    		Wnt β-catenin Cancer
    CCT 031374 hydrobromid is a potent inhibitor of β-catenin/transcription factor (TCF) complex signaling. CCT031374 inhibits TCF-dependent transcription of genes of Wnt signaling pathway. CCT 031374 has antitumor activity .
    CCT031374 hydrobromide
  • HY-157126
    Pterostilbene-isothiocyanate

    PTER-ITC

    		 β-catenin Cancer
    Pterostilbene-isothiocyanate (PTER-ITC) exhibits potent anticancereffects in vitro. Pterostilbene-isothiocyanate against human osteosarcoma cells by abrogating the β-catenin/TCF-4 interaction .
    Pterostilbene-isothiocyanate
  • HY-B1360R
    Chlorquinaldol (Standard)

    Chloquinan (Standard)

    		 Antibiotic Bacterial Fungal β-catenin Reference Standards Apoptosis Infection Cancer
    Chlorquinaldol (Standard) is the analytical standard of Chlorquinaldol. This product is intended for research and analytical applications. Chlorquinaldol (Chloquinan) is an antibacterial agent with the potential use in topical skin conditions and vaginal infections. Chlorquinaldol is a β-catenin/TCF4 inhibitor, showing anti-proliferation, anti-migration, and apoptosis-inducing activity in cancer cells .
    Chlorquinaldol (Standard)
  • HY-P11660
    β-catenin-IN-10

    		β-catenin Wnt Androgen Receptor Cancer
    β-catenin-IN-10 is a β-catenin:TCF4 interaction inhibitor with an IC50 of 5.44 μM. β-catenin-IN-10 inhibits the Wnt and AR signaling pathways with IC50 values of 0.105 μM and 1.02 μM, respectively. β-catenin-IN-10 suppresses the proliferation of castration-resistant prostate cancer cells. β-catenin-IN-10 is applicable to research related to prostate cancer .
    β-catenin-IN-10
  • HY-181560
    SLD1121

    		Wnt β-catenin Metabolic Disease
    SLD1121 is an agonist of the Wnt/β-catenin signaling pathway that enhances Wnt signaling by targeting LRP6 (Kd: 4.52-7.49 nM). SLD1121 interacts with the intracellular domain of LRP6, stabilizes LRP6, promotes its nuclear translocation, and facilitates its binding to β-catenin, TCF4 or LEF1 in the nucleus, thereby inducing the expression of Wnt-regulated genes and stem cell-related genes. SLD1121 induces the transition of hair follicles from telogen to anagen in the mouse hair growth cycle and promotes hair growth in mice. SLD1121 is applicable to hair loss-related research .
    SLD1121
  • HY-133093
    Murayaquinone

    PKF118-774

    		 Parasite β-catenin Infection Cancer
    Murayaquinone (PKF118-774) is a β-catenin/Tcf4 complex inhibitor with an IC50 of 2.4 μM. Murayaquinone is a nematicidal agent found in Streptomyces sp. AN140557 .
    Murayaquinone
  • HY-101486R
    LF3 (Standard)

    		β-catenin Reference Standards Cancer
    LF3 (Standard) is the analytical standard of LF3 (HY-101486). This product is intended for research and analytical applications. LF3 is an antagonist of the β-Catenin/TCF4 interaction with antitumor activity; has an IC50 of 1.65 μM .
    LF3 (Standard)
  • HY-186001
    RMC-9945

    RM-044

    		 Ras β-catenin Cancer
    RMC-9945 (RM-044) is a KRAS inhibitor and selective, covalent, orally active RAS(ON) G12D inhibitor. RMC-9945 increases β-Catenin/TCF transcriptional activity. RMC-9945 exerts durable disease control in preclinical colorectal cancer models of early liver metastasis .
    RMC-9945

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: